Cephalon, Barr Settle Fentora Patent Battles
In a filing Thursday with the U.S. Securities and Exchange Commission, Cephalon said it had entered into a binding agreement-in-principle with Barr, along with Barr Laboratories Inc, to settle its pending patent infringement lawsuit over Barr's generic version of the fentanyl buccal tablet.
Under the terms of the deal, Cephalon agreed to grant Barr a nonexclusive, royalty-free right to market and sell a generic version of Fentora...
Already a subscriber? Click here to login